GSK will pump £275m ($360m) into its UK manufacturing network and says the country has a “leading position in life sciences” despite the recent Brexit vote.
BASF has said it saw lower demand for its remaining APIs in the second quarter.
Slovakian CDMO Saneca Pharma will make more than 20 generic products for Xantis after selling the registration dossiers to the Swiss firm.
Bioprocess equipment vendors Pall and Sartorius have each cited demand for single-use technologies as a growth driver in the first half 2016.
The US FDA says it identified “significant deviations” from manufacturing standards a facility in Denmark operated by allergy immunotherapy developer ALK-Abello (ALK).
The US FDA will not approve the candidate eye pain eye treatment Dextenza until developer Ocular Therapeutix addresses concerns about how the product is made.